Statements (59)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:vaccine
|
gptkbp:accessories |
gptkb:various_countries
|
gptkbp:approves |
gptkb:Russia
fast-tracked in some countries |
gptkbp:average_temperature |
-18° C
|
gptkbp:clinical_trial |
over 40,000
multiple countries Phase III February 2021 completed Phase I, II, III |
gptkbp:collaborations |
with global health organizations
|
gptkbp:developed_by |
Gamaleya Research Institute
|
gptkbp:disease_resistance |
varies by region
|
gptkbp:distribution |
over 70 countries
|
gptkbp:dosage_form |
gptkb:battle
2 91.6% |
gptkbp:economic_impact |
considerable
|
gptkbp:has_variants |
studied
|
https://www.w3.org/2000/01/rdf-schema#label |
Sputnik V vaccine
|
gptkbp:is_effective_against |
gptkb:The_Lancet
|
gptkbp:is_vulnerable_to |
gptkb:virus
gptkb:Ability gptkb:significant ongoing affordable logistical issues strong immune response limited in some regions continuing for new variants reduction in COVID-19 cases against severe disease adverse event monitoring ongoing repurposed adenoviral vector |
gptkbp:manager |
intramuscular
|
gptkbp:manufacturer |
Russian Direct Investment Fund
|
gptkbp:market |
ongoing
|
gptkbp:moral |
discussed in public forums
|
gptkbp:operating_hours |
3 weeks apart
|
gptkbp:origin |
gptkb:Sputnik_satellite
|
gptkbp:partnerships |
international organizations
various pharmaceutical companies |
gptkbp:public_awareness |
implemented in various countries
|
gptkbp:public_perception |
mixed
|
gptkbp:receives_funding_from |
government and private sources
|
gptkbp:regulatory_compliance |
multiple countries
faced in some regions |
gptkbp:release_date |
August 2020
|
gptkbp:safety_features |
generally well tolerated
|
gptkbp:side_effect |
fatigue
headache fever injection site pain |
gptkbp:status |
Emergency Use Listing
|
gptkbp:storage |
up to 6 months at -18° C
|
gptkbp:targets |
gptkb:COVID-19
|
gptkbp:type |
viral vector vaccine
|
gptkbp:bfsParent |
gptkb:COVID-19_pandemic_in_Iran
|
gptkbp:bfsLayer |
6
|